Two products now have updated
Australian Public Assessment
Report (AusPAR) guidance from the
Therapeutic Goods Administration.
Celgene’s Revlimid (lenalidomide),
indicated for treatment of patients
with newly diagnosed multiple
myeloma, has additional strength
capsules.
NOAC Pradaxa (dabigatran) from
Boehringer Ingelheim has extended
indications.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Feb 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.